WEBULL
News
SESN
0.6288
0.00%
0.0000
BUZZ-U.S. STOCKS ON THE MOVE-Venture Global, TSMC, Oracle
Reuters · 10/10/2025 16:09
Carisma Therapeutics to Be Delisted from Nasdaq Will Trade on OTCID Amid Regulatory Noncompliance
Reuters · 10/09/2025 21:12
Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares
Reuters · 10/08/2025 20:17
Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares
Reuters · 10/03/2025 21:25
Ocugen Inc. Announces Termination of Merger Agreement with Carisma Therapeutics Due to Funding Shortfall
Reuters · 09/18/2025 15:01
Carisma Therapeutics Amends Agreement with Moderna, Receives $4 Million Payment
Reuters · 09/18/2025 13:15
Ocugen Inc. Finalizes Merger Agreement with Carisma Therapeutics, Inc., Including a $5 Million Investment in Common Stock
Reuters · 09/05/2025 20:12
Carisma Therapeutics Inc. Announces $5 Million Share Purchase Agreement with Ocugen in Private Placement
Reuters · 08/29/2025 20:21
Carisma Therapeutics Inc. Held Special Stockholders Meeting
Reuters · 08/08/2025 20:07
Carisma Therapeutics Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Listing Rules
Reuters · 07/15/2025 20:16
CARISMA THERAPEUTICS INC - TO BE RENAMED ORTHOCELLIX AND TRADE UNDER TICKER OCLX
Reuters · 06/23/2025 11:30
CARISMA THERAPEUTICS: TO ISSUE TO PRE-MERGER ORTHOCELLIX STOCKHOLDER SHARES OF CO'S COMMON STOCK AS MERGER CONSIDERATION
Reuters · 06/23/2025 11:30
Based on the provided financial report articles, the title of the article is: "Carisma Therapeutics Inc. (Form 10-K)
Press release · 04/07/2025 12:05
Carisma Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/31/2025 23:04
CARISMA THERAPEUTICS INC: HAS PAUSED ALL RESEARCH AND DEVELOPMENT ACTIVITIES AT THIS TIME, PENDING OUTCOME OF REVIEW
Reuters · 03/31/2025 20:30
More
Webull provides a variety of real-time SESN stock news. You can receive the latest news about Sesen Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SESN
Carisma Therapeutics Inc., formerly Sesen Bio, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The Company's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.